|
|
LIN LABORATORY
My laboratory studies the cancer biology of Signal Transducer and Activator of Transcription 3 (STAT3) oncogenic pathway and STAT1 tumor suppressor in human cancers. Constitutive activation of STAT3 is frequently detected in most types of human cancers. We are studying the activation of STAT3 by upstream tyrosine kinases, HGF and SDF-1 and how they may function in STAT3-mediated cell survival, proliferation, tumor angiogenesis, and tumor cells/stroma fibroblasts interaction in cancer cells. The laboratory is also developing novel structure-based design of small molecule compounds that selectively target STAT3 oncogenic pathway in cancer cells as a new cancer therapeutic approach. Further, we are examining the interaction between STAT1 and p53 tumor suppressor and how they cooperate to mediate tumor suppression in cancer cells.
|
| Education |
| 1996 |
|
Post-doctoral training |
|
|
|
Princeton University, Department of Molecular Biology, Princeton, New Jersey |
| 1991 |
|
Ph.D. |
|
|
|
University of Delaware, Department of Biological Sciences, Newark, Delaware |
| Professional Experience |
| 2005- PRES |
Associate Professor with Tenure, Department of Pediatrics, College of Medicine and Public Health, Ohio State University. |
| 2005- PRES |
Investigator, Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital. |
| 2005- PRES |
Graduate Faculty, Integrated Biomedical Science, Molecular, Cellular & Developmental Biology, and Ohio State Biochemistry Graduate Programs, Ohio State University. |
| 2004- PRES |
Investigator, Center for Childhood Cancer, The Research Institute at Nationwide Children's Hospital. |
| 2001- 2004 |
Graduate Faculty in Cellular and Molecular Biology Graduate Program and Cancer Biology Training Program at the University of Michigan Health System. |
| 1998- 2004 |
Assistant Professor (Tenure Track) at the Division of Gynecologic Oncology, University of Michigan Comprehensive Cancer Center. |
| 1997- 1998 |
Research Investigator/Instructor, Department of Dermatology, University of Michigan Medical Center. |
| Selected Publications |
|
Chen C., Hsieh F., Lieblein, J.C., Brown J., Chan C., Wallace J., Cheng G., Hall B., and Lin J. Stat3 activation in human endometrial and cervical cancers. British Journal of Cancer In Press (2007).
|
| Song H., Wang R., Wang S., and Lin, J. A small molecule inhibitor discovered through virtual database screening inhibits Stat3 oncogenic function in breast cancer cells. Proc Natl Acad Sci USA 102:4700-4725 (2005). |
| Jin X., Gossett D., Wang S., Yang D., Reynolds R.K., and Lin, J. Inhibition of AKT pathway in endometrial cancer cells harboring PTEN mutation by an AKT small moleculare inhibitor. British Journal of Cancer 91:1808-1812 (2004). |
| Tang H., Sondak V. and Lin J. A Modified p53 Enhances Apoptosis in Sarcoma Cell Lines Mediated by Doxorubicin. British Journal of Cancer 90: 1285-92 (2004). |
| Song H., Jin X., and Lin J. Stat3 up-regulates MEK5 expression in human breast cancer cells. Oncogene 23:8301-8309 (2004). |
| Lin J., Jin X., Rothman K., Lin H. and Burke W.M. Inhibition of Stat3 by p53 tumor suppressor in breast cancer cells. Cancer Research 62: 376-380 (2002). |
| Lu W., Lin J. and Chen J. Expression of p14ARF overcomes tumor resistance to p53. Cancer Research 62: 1305-1310 (2002). |
| Lin J., Tang T., Jin X. and Hsieh J. P53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 21: 3082-3088 (2002). |
| Burke M.W., Jin X., Lin H., Huang M., Liu R., Reynolds Y.R.K. and Lin J. Inhibition of constitutively active Stat3 in ovarian and breast cancer cells. Oncogene 20: 7925-7934 (2001). |
| Lin J., Jin X., Page C., Sondak V., Jiang G., and Reynolds K. A modified p53 overcomes mdm2-mediated oncogenic transformation. Cancer Research 60:5895-5901 (2000). |
|
